China-based InxMed has completed a USD 34 million Series C round led by Fosun Health Capital to advance its pipeline targeting tumour resistance mechanisms in solid cancers. The clinical-stage biotech has raised over USD 130 million since its 2018 founding to develop focal adhesion kinase inhibitors and combination therapies addressing treatment-refractory malignancies. The company highlighted ongoing global partnership discussions to maximise the value of its differentiated programs currently in multiple clinical trials.

The funding follows China's biotech market recovery, with alignment between InxMed's development milestones and improving capital conditions. Fosun Health Capital praised the team's scientific insights and execution capabilities in building a pipeline with significant competitive advantages for hard-to-treat cancers.

PharmCube's MedAlpha® database shows that the Hong Kong Stock Exchange (HKEX) has enjoyed continuous recovery throughout this year. Click here to request a free trial for MedAlpha®.